Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.68 |
| ▸ | ENPP2 | Q13822 | 7/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25160021 | 0.88 | ENPP2 (0.55) | MGLLENPP2CA1CA2CA4 | |
| SCHEMBL29953646 | 0.86 | ENPP2 (0.79) | MGLLENPP2PTPN5XDHSLC22A12 | |
| SCHEMBL22484828 | 0.86 | ENPP2 (0.79) | MGLLENPP2PTPN5XDHSLC22A12 | |
| SCHEMBL12181457 | 0.86 | MGLL (0.91) | MGLLENPP2CA1CA2CA4 | |
| SCHEMBL16016633 | 0.85 | ENPP2 (0.65) | MGLLENPP2CA1CA2PTPN5 | |
| SCHEMBL1542734 | 0.84 | MGLL (0.95) | MGLLENPP2CA1CA2CA4 | |
| SCHEMBL1542869 | 0.84 | MGLL (0.95) | MGLLENPP2CA1CA2CA4 | |
| SCHEMBL29641494 | 0.84 | MGLL (0.95) | MGLLENPP2CA1CA2CA4 | |
| SCHEMBL30423063 | 0.84 | MGLL (0.95) | MGLLENPP2CA1CA2CA4 | |
| SCHEMBL17775874 | 0.82 | PTPN5 (0.49) | PTPN5XDHSLC22A12GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230217666-A1 | Organic Electroluminescent Element And Novel Iridium Complex | UDC IRELAND LTD (IE) | 2023-07-06 | — | — | US | disclosed |
| US-20230217666-A1 | Organic Electroluminescent Element And Novel Iridium Complex | UDC IRELAND LTD (IE) | 2023-07-06 | — | — | US | disclosed |
| US-20210057666-A1 | Organic Electroluminescent Element And Novel Iridium Complex | UDC IRELAND LTD (IE) | 2021-02-25 | — | — | US | disclosed |
| US-10854835-B2 | Organic electroluminescent element and novel iridium complex | UDC IRELAND LIMITED (IE) | 2020-12-01 | — | — | US | disclosed |
| US-10340471-B2 | Organic electroluminescent element and novel iridium complex | UDC IRELAND LIMITED (IE) | 2019-07-02 | — | — | US | disclosed |
| US-9000421-B2 | Organic electroluminescent element, materials for organic electroluminescent element, and light emitting device, display device, or illumination device, each using the element, and compounds used in the element | UDC IRELAND LIMITED (IE) | 2015-04-07 | — | — | US | disclosed |
| US-9000421-B2 | Organic electroluminescent element, materials for organic electroluminescent element, and light emitting device, display device, or illumination device, each using the element, and compounds used in the element | UDC IRELAND LIMITED (IE) | 2015-04-07 | — | — | US | disclosed |
| US-20140252333-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT AND NOVEL IRIDIUM COMPLEX | Alexamdra House, The Sweepstakes (IE) | 2014-09-11 | — | — | US | disclosed |
| US-20140252333-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT AND NOVEL IRIDIUM COMPLEX | Alexamdra House, The Sweepstakes (IE) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10340471-B2 | Organic electroluminescent element and novel iridium complex | CTCF, AP1M1, CLIC4 | MGLL 4263/4885ENPP2 4614/4885CA1 1052/4885 |
| US-20230217666-A1 | Organic Electroluminescent Element And Novel Iridium Complex | CTCF, AP1M1, CLIC4 | MGLL 3890/4885ENPP2 4415/4885CA1 987/4885 |
| US-10854835-B2 | Organic electroluminescent element and novel iridium complex | CTCF, AP1M1, CLIC4 | MGLL 4263/4885ENPP2 4614/4885CA1 1052/4885 |
| US-20210057666-A1 | Organic Electroluminescent Element And Novel Iridium Complex | CTCF, AP1M1, CLIC4 | MGLL 4263/4885ENPP2 4614/4885CA1 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.